Clinical Trial Update: Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy with low-dose docetaxel in metastatic hormone-sensitiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Darolutamide (darolutamide)

Snippet

Sponsor: Yonghong Li | Conditions: mHSPC | Phase 2 | Status: NOT_YET_RECRUITING